1A80 Stock Overview
An in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.14 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$0.69 |
| Beta | 0.55 |
| 1 Month Change | -28.30% |
| 3 Month Change | -15.56% |
| 1 Year Change | -70.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1A80 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.1% | -3.3% | -2.0% |
| 1Y | -70.2% | -8.5% | 6.9% |
Return vs Industry: 1A80 underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 1A80 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 1A80 volatility | |
|---|---|
| 1A80 Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1A80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1A80's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 134 | Jack Phillips | acceleratediagnostics.com |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
| 1A80 fundamental statistics | |
|---|---|
| Market cap | €27.84m |
| Earnings (TTM) | -€51.23m |
| Revenue (TTM) | €11.41m |
2.4x
P/S Ratio-0.5x
P/E RatioIs 1A80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1A80 income statement (TTM) | |
|---|---|
| Revenue | US$11.91m |
| Cost of Revenue | US$9.02m |
| Gross Profit | US$2.89m |
| Other Expenses | US$56.34m |
| Earnings | -US$53.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 24.25% |
| Net Profit Margin | -448.85% |
| Debt/Equity Ratio | -119.6% |
How did 1A80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Accelerate Diagnostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lavin | BTIG |
| Garrett Nelson | CFRA Equity Research |
| Alexander Nowak | Craig-Hallum Capital Group LLC |